Adaptive COO sells 92,823 shares in option trades
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported a series of option exercises and related share sales.
Rhea-AI Filing Summary
Adaptive Biotechnologies Corp President and COO Julie Rubinstein reported a series of option exercises and related share sales. Over March 3–5, 2026, she exercised fully or partially vested stock options into common stock and sold 92,823 shares in open-market transactions at prices reported around the mid-teens per share.
The sales were effected under a Rule 10b5-1 trading plan adopted on November 18, 2025, meaning they followed a prearranged schedule. After these transactions, Rubinstein held 575,235 shares of common stock directly. Reported sale prices are weighted averages of multiple trades, with ranges disclosed between $15.11 and $16.94 per share.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
16 txns
Insider
RUBINSTEIN JULIE
Role
President and COO
Sold
92,823 shs ($1.49M)
Approx. gross sale proceeds
$1.49M
Approx. exercise cost
$722K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 11,881 | $0.00 | $0.00 |
| Exercise | Common Stock | 14,722 | $6.55 | $96K |
| Exercise | Common Stock | 11,881 | $12.14 | $144K |
| Sale | Common Stock | 30,941 | $16.00 | $495K |
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 11,881 | $0.00 | $0.00 |
| Exercise | Common Stock | 14,722 | $6.55 | $96K |
| Exercise | Common Stock | 11,881 | $12.14 | $144K |
| Sale | Common Stock | 30,941 | $16.60 | $514K |
| Exercise | Stock Option (right to buy) | 14,722 | $0.00 | $0.00 |
| Exercise | Stock Option (right to buy) | 11,881 | $0.00 | $0.00 |
| Exercise | Common Stock | 14,722 | $6.55 | $96K |
| Exercise | Common Stock | 11,881 | $12.14 | $144K |
| Sale | Common Stock | 24,423 | $15.49 | $378K |
| Sale | Common Stock | 6,518 | $16.33 | $106K |
Holdings After Transaction:
Stock Option (right to buy) — 578,860 contracts (Direct);
Common Stock — 575,235 shares (Direct)
Footnotes (7)
- F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025.
- F2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.11 to $16.10, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F3. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.11 to $16.56, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F4. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.35 to $16.94, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F5. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.74 to $16.30, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F6. The option is fully vested and exercisable.
- F7. The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider activity did ADPT executive Julie Rubinstein report on this Form 4?
Julie Rubinstein, President and COO of Adaptive Biotechnologies (ADPT), exercised stock options and sold 92,823 common shares. The transactions combined option exercises with open-market sales executed over several days in early March 2026 at mid-teen share prices.
What types of securities were involved in Julie Rubinstein’s ADPT Form 4 transactions?
The Form 4 shows activity in both stock options and common stock. Rubinstein exercised options (stock options, right to buy) into common shares, then conducted open-market sales of portions of that common stock at weighted-average prices.
How are the option grants for ADPT’s Julie Rubinstein structured and vested?
One reported option is noted as fully vested and exercisable. Another vests with respect to one-quarter on March 4, 2023, with 1/48 of the shares vesting monthly thereafter for each full month of continuous service until fully vested.
AI-generated analysis. How Rhea-AI works. Not financial advice.
